Sfoglia per AUTORE
COSCIA M
Collezione ASL Vercelli

  

Items : 5

Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL. in Blood / Blood. 2022 Dec 1;140(22):2348-2357. doi: 10.1182/blood.2022016901.

2022
ASL Vercelli
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Moia R; Scarfò L; Ghia P; Perotta E; Heltai S; Albi E; Scarano E; Schiattone L; Farina L; Ranghetti P; Colia M; Capasso A; Varettoni M; Coscia M; Rivela P; Laurenti L; Ferrario A; Motta M; Sancetta R; Reda G; Deodato M;

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. in Journal of hematology & oncology / J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.

2022
AO Cuneo
ASL Vercelli
ASL Cuneo 1
AOU Alessandria

Ghia P; Stamatopoulos K; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Carrier M; Wróbel T; Segundo LYS; Varettoni M; Visentin A; Vitale C; Vukovic V; Shrestha A; Šimkovi? M; Smirnova S; Špa?ek M; Sportoletti P; Stanca O; Wasik-Szczepanek E; Stavroyianni N; Te Raa D; Tomic K; Tonino S; Trentin L; Van Der Spek E; van Gelder M; et alii...

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. in Cancer medicine / Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.

2020
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Novara

Vignetti M; Foà R; Ghia P; Cimino G; Cavallari M; Cucci R; de la Serna J; Ferrarini I; Medina Perez A; Mauro FR; Coscia M; Di Raimondo F; Farina L; Molica S; Gaidano G; Doubek M; Ilariucci F; Tedeschi A; Marchetti M; Spacek M; Trentin L; Billio A; Ujjani CS; Roeker L; Orlandi EM; Schuster SJ; Shah NN; Sehgal AR; Pu JJ; et alii...

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli
AOU Novara

Boccadoro M; Gattei V; Foà R; Massaia M; Gaidano G; Zenz T; Bernardi R; Mauro FR; Laurenti L; Del Poeta G; Kodipad AA; Omedè P; Magliulo D; Rossi D; Marchetti M; Bonello L; Pozzato G; Bo MD; Kopecka J; Bomben R; Salvetti C; Riganti C; Todaro M; Vitale C; Griggio V; Coscia M;

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. in Haematologica / Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

2018
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli

Eyre TA; Kennedy B; Schuh A; Smolej L; Montillo M; Cortelezzi A; Ciolli S; Forconi F; Gonzalez M; Re F; Gaidano G; Molica S; Marchetti M; Ilariucci F; Meneghini V; Chiarenza A; Marasca R; Amendola A; Billio A; Visco C; Mauro FR; Galieni P; Orlandi EM; Farina L; Delgado AR; Musuraca G; Laurenti L; Coscia M; Perez AM; et alii...